Personal Finance

Make more, save more, spend smarter, and keep more of what you earn

Business News

Stock market news & analysis


Mach One’s Co-Development Plans (OTC:MNCN)

By Jyotsna Ramani on 11/17/2009 – 7:00 am PSTOne Comment

Mach One Corporation (OTC:MNCN) has announced that they have completed the first tranche of their investment in PanTheryx, Inc. as stipulated in the recent Letter of Understanding signed in August 2009. This action expedites development and introduction plans for an orally administered antibody therapeutic for treatment of pediatric diarrhea. The co-developed pediatric diarrhea product will initially be targeted for commercial introduction in India, where PanTheryx maintains a sales force and contract sales relationships. Both the companies are working on treatment of pediatric diarrhea as it is the second largest killer of children between age of birth to adolescence, with an estimated 1.4 million children dying each year from this illness.

Mach One Corporation is a global wellness company that provides biotechnology based solutions for positive, long term health and longevity benefits for humans and disease-threatened animals for commercial operations. On the other hand, PanTheryx Medical Pvt. Ltd. (a wholly owned subsidiary of PanTheryx, Inc.) is an emerging Indian company creating and selling healthcare products, including the acquisition, development, and commercialization of advanced technologies, for introduction into the Indian healthcare market. CEO of Mach One Corporation, Tad Ballantyne stated that the mutual goal for both the healthcare companies is to address this enormous health issue of pediatric diarrhea and through combined efforts they will be able to come out with new medical innovation.

One Comment »

  • Dick Puffer says:

    Mach One Corporation seems to be in the business of generating press releases of deals with no real substance. Quite frankly I do not think there is anything very real in Mach One. It seems like a series of financings with related parties or companies with no real revenues.

Leave a comment!

Add your comment below, or trackback from your own site. You can also subscribe to these comments via RSS.

Be nice. Keep it clean. Stay on topic. No spam.

You can use these tags:
<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

This is a Gravatar-enabled weblog. To get your own globally-recognized-avatar, please register at Gravatar.